Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Garnier Touts “Progressive Blockbuster” As Model For Future Drugs

Executive Summary

One way to handle an increasingly cautious FDA would be to take a different tack on development - pursuing "progressive blockbusters" that are approved on a population-by-population basis to prove the drugs are safe in different patient types rather than trying to make a traditional blockbuster big splash, according to GlaxoSmithKline CEO JP Garnier

You may also be interested in...



Wyeth Looks To Specialty Markets As Generics Challenge Current Model

Wyeth's R&D pipeline is evolving the firm toward more specialized areas as several of its blockbuster products face patent expirations and generic challenges

FDA To Review Vytorin Data: ENHANCEd Label To Follow?

FDA expects to complete a review of data from the ENHANCE study for Merck and Schering-Plough's Vytorin within nine months, Office of New Drugs Director John Jenkins announced Jan. 25

GSK Has 25 Potential Launches By Decade’s End; Neuroscience A Focus

GlaxoSmithKline could see 25 new drug launches in the time period from 2007 to 2009, including 12 new chemical entities, eight product line extensions and five vaccines, R&D Chairman Moncef Slaoui stated during a pipeline update with investors Dec. 13 in New York City

Related Content

UsernamePublicRestriction

Register

PS049288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel